Phase Forward Named Best Life Sciences Partner; Electronic Data Capture (EDC) Product InForm(TM) Best Software-as-a-Service
WALTHAM, Mass.--(BUSINESS WIRE)--June 6, 2007--Phase Forward
(NASDAQ: PFWD), a leading provider of data management solutions for
clinical trials and drug safety, today announced that it has received
two Global Partner Awards from Cognos: "Best Life Sciences Partner"
and "Best Software-as-a-Service (SaaS)." The awards recognize partners
excelling at innovation, influence and thought leadership.
In addition, Phase Forward's InForm(TM) Integrated Trial
Management (ITM) system (version 4.5) has achieved "Powered by Cognos"
status. Phase Forward leverages Cognos technology to provide a robust
solution for generating clinical trial data reports and analyzing
data. With timely and insightful views into trial data, sponsors have
the ability to mitigate risks and improve overall trial conduct.
"Life sciences companies are under intense pressure to deliver new
drugs in record time and Phase Forward's flexible set of
out-of-the-box reporting and analysis tools help streamline a
previously time-intensive reporting process," said Bill Stevens,
senior director, Life Sciences Solutions, Cognos. "The combination of
our technologies helps facilitate better clinical trial information
access and lets study teams focus on clinical data analysis and action
- not report creation and maintenance."
"Our longstanding strategic alliance with Cognos has proven to be
a powerful competitive advantage, and this latest acknowledgement
speaks to the stability and scalability of our products," said Steve
Rosenberg, Senior Vice President, Phase Forward. "Cognos' breadth of
business intelligence experience and depth of expertise help us to
deliver the solutions that turn clinical trial data into actionable
information - and help users make better informed decisions as a
result."
Award winners were announced at the Partner Summit Awards ceremony
held at the recent Global Partner Summit as part of Cognos Forum 2007.
About Phase Forward
Phase Forward is a leading provider of integrated data management
solutions for clinical trials and drug safety. The company offers
proven solutions for electronic data capture (InForm(TM)), clinical
data management (Clintrial(TM)), clinical trials signal detection
(CTSD(TM)), strategic pharmacovigilance (WebVDME(TM) and Signal
Management), adverse event reporting (Clintrace(TM)) and applied data
standards (WebSDM(TM)). In addition, the company provides services in
the areas of application implementation, hosting and validation, data
integration, business process optimization, safety data management and
industry standards. Phase Forward's products and services have been
utilized in over 10,000 clinical trials involving more than 1,000,000
clinical trial study participants at over 250 organizations and
regulatory agencies worldwide including: AstraZeneca, Boston
Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and
Drug Administration, or FDA, GlaxoSmithKline, Harvard Clinical
Research Institute, Merck & Co., Merck Serono, Novartis, Novo Nordisk,
PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis,
Schering-Plough Research Institute, Tibotec, the U.K. Medicines and
Healthcare Products Regulatory Agency and Servier. Additional
information about Phase Forward is available at www.phaseforward.com.
About Cognos
Cognos, the world leader in business intelligence and performance
management solutions, provides world-class enterprise planning and BI
software and services to help companies plan, understand and manage
financial and operational performance.
Cognos brings together technology, analytical applications, best
practices, and a broad network of partners to give customers a
complete performance system. The Cognos performance system is an open
and adaptive solution that leverages an organization's ERP, packaged
applications, and database investments. It gives customers the ability
to answer the questions - How are we doing? Why are we on or off
track? What should we do about it? - and enables them to understand
and monitor current performance while planning future business
strategies.
Cognos serves more than 23,000 customers in more than 135
countries, and its top 100 enterprise customers consistently
outperform market indexes. Cognos performance management solutions and
services are also available from more than 3,000 worldwide partners
and resellers. For more information, visit the Cognos Web site at
http://www.cognos.com.
Cautionary Statement
Certain statements made in this press release that are not based
on historical information are forward-looking statements which are
made pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. This press release contains express or
implied forward-looking statements relating to, among other things,
the performance and features of Phase Forward's products and services
and the ability of Phase Forward's customers to realize benefits from
the use of Phase Forward's products and services. These statements are
neither promises nor guarantees, but are subject to a variety of risks
and uncertainties, many of which are beyond Phase Forward's control,
which could cause actual results to differ materially from those
contemplated in these forward-looking statements. In particular, the
risks and uncertainties include, among other things, the ability of
Phase Forward's customers to realize benefits from the use of its
products and services, changes in regulatory requirements applicable
to Phase Forward's customers, the manner in which Phase Forward's
customer and partner and its partner's customers conduct business and
the possibility that their needs or plans may change over time, and
competition. Existing and prospective investors are cautioned not to
place undue reliance on these forward-looking statements, which speak
only as of the date hereof. Phase Forward undertakes no obligation to
update or revise the information contained in this press release,
whether as a result of new information, future events or circumstances
or otherwise. For additional disclosure regarding these and other
risks faced by Phase Forward, see the disclosure contained in Phase
Forward's public filings with the Securities and Exchange Commission
including, without limitation, its most recent Quarterly Report on
Form 10-Q.
CONTACT: Phase Forward
Gretchen Dock, 781-902-4413
gretchen.dock@phaseforward.com
or
CHEN PR, Inc.
Juli Greenwood, 781-672-3137
jgreenwood@chenpr.com
SOURCE: Phase Forward
